Abbott Laboratories (VIE:ABT)
Austria · Delayed Price · Currency is EUR | Market Cap | 155.19B -23.6% |
| Revenue (ttm) | 37.75B +5.7% |
| Net Income | 5.54B -51.3% |
| EPS | 3.17 -51.3% |
| Shares Out | n/a |
| PE Ratio | 28.03 |
| Forward PE | 18.68 |
| Dividend | 2.07 (2.32%) |
| Ex-Dividend Date | Jan 15, 2026 |
| Volume | n/a |
| Average Volume | 8 |
| Open | 88.90 |
| Previous Close | 89.05 |
| Day's Range | 88.45 - 89.24 |
| 52-Week Range | 88.19 - 121.90 |
| Beta | n/a |
| RSI | 37.01 |
| Earnings Date | Apr 16, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform
Broadens access to Abbott's Precision Oncology tests across more than 1,600 community cancer care centers and 4,700 providers in Flatiron's North America network, helping accelerate informed treatment...
Abbott hosts conference call for first-quarter earnings
ABBOTT PARK, Ill., March 26, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2026 financial results on Thursday, April 16, before the market opens.
John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening
Potentially awkward conversations and 90s nostalgia combine to drive accessible screening for adults 45+ Learn more at Cologuard.com/TheTalk ABBOTT PARK, Ill., March 24, 2026 /PRNewswire/ -- Abbott (N...
Abbott completes acquisition of Exact Sciences
Establishes Abbott as a leader in fast-growing cancer screening and diagnostics segments Advances Abbott's mission to make healthcare more accessible and give people more control over their health ABB...
Abbott acquisition of Exact Sciences set to close on March 23, 2026
Announcement follows receipt of all regulatory clearances necessary for closing Transaction enables Abbott to enter and lead in fast-growing cancer screening and diagnostics segments, serving millions...
Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit
MINNEAPOLIS--(BUSINESS WIRE)--Pivot Bio, one of the world's leading innovative agtech companies, will be taking the stage at the World Agri-Tech Innovation Summit taking place March 16–18, 2026. Chris...
Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
U.K. FreeDM2 randomized controlled trial: At four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks 1,2 Improve...
Exact Sciences Stockholders Approve Acquisition by Abbott
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted t...
Abbott declares 409th consecutive quarterly dividend
ABBOTT PARK, Ill., Feb. 20, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key
LISTING LINK: https://www.premiersothebysrealty.com/single-family/mfr/a4681242/6610-gulf-of-mexico-drive-longboat-key-fl-34228 DROPBOX: https://tours.coastalhomephotography.net/public/vtour/display/23...
Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation
Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) Sys...
Abbott recalls glucose sensors after seven deaths linked to faulty readings
Abbott has recalled certain glucose monitoring sensors after reports linked the devices to seven deaths and 860 serious injuries, the U.S. health regulator said on Wednesday.
Is The Fall In Abbott Stock Justified?
Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, align...
Abbott faces India scrutiny in cough syrup abuse investigation, documents show
Indian drugmaker Abbott Healthcare's supply chain is being scrutinised as part of a wider investigation into the alleged misuse of its codeine-based cough syrup which is prone to abuse by addicts, doc...
Abbott Laboratories Raised Prices, Prompting Sales Slump
The medical-products maker's shares tumbled after its quarterly profit and sales underwhelmed investors.
Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Thursday.
MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off
Intel's (INTC) recent rally isn't the only one investors should pay attention to, says Diane King Hall. She points to Moderna (MRNA) hitting a 52-week high after a trial drug to treat melanoma posted ...
Cramer's Mad Dash: Abbott Labs
CNBC's Jim Cramer delivers his daily Mad Dash.
Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints
Abbott Laboratories (NYSE: ABT) stock fell on Thursday after the company reported fourth-quarter 2025 sales and the first-quarter 2026 earnings outlook below expectations.
Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.
Abbott reports fourth-quarter sales that miss analysts' estimates.
Abbott misses quarterly revenue estimates on weakness in diagnostics segment
Abbott missed Wall Street estimates for quarterly revenue on Thursday, hit by weakness in its diagnostic business which has been volatile due to sharp decline in COVID-19 testing demand and a freeze o...
Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percent Full-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 perc...
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings
Abbott Laboratories (NYSE: ABT) will release earnings for the fourth quarter before the opening bell on Thursday, Jan. 22.
Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms
Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, is designed with dual-energy to treat atrial fibrillation patients with the most challenging cases It can deliver both radiofrequency energy...